KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas

Modern Pathology

Volumn 26, Issue 10, 2013, Pages 1346-1354

  Krasinskas, Alyssa M ^a   Moser, A James ^b   Saka, Burcu ^c   Adsay, N Volkan ^c   Chiosea, Simion I ^a  

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fluorescence in situ hybridization; KRAS; Mutant allele specific imbalance; Pancreatic cancer; Undifferentiated carcinoma

Indexed keywords

K RAS PROTEIN;

ADULT; AGED; ALLELIC IMBALANCE; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME 12; DISEASE FREE SURVIVAL; ELECTROPHORESIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MAJOR CLINICAL STUDY; MALE; MUCINOUS CYSTIC NEOPLASM; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PRIORITY JOURNAL; UNDIFFERENTIATED CARCINOMA; UNIPARENTAL DISOMY;

AGED; ALLELES; ALLELIC IMBALANCE; CARCINOMA; CARCINOMA, PANCREATIC DUCTAL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PANCREATIC NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84885018386     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.71     Document Type: Article

References (33)

1. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53: 549-554.
2. Smit VT, Boot AJ, Smits AM, et al. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988;16: 7773-7782.
3. Hruban RH, van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993;143: 545-554.
4. Gocke CD, Dabbs DJ, Benko FA, et al. KRAS oncogene mutations suggest a common histogenetic origin for pleomorphic giant cell tumor of the pancreas, osteoclastoma of the pancreas, and pancreatic duct adenocarcinoma. Hum Pathol 1997;28: 80-83.
5. Westra WH, Sturm P, Drillenburg P, et al. K-ras oncogene mutations in osteoclast-like giant cell tumors of the pancreas and liver: genetic evidence to support origin from the duct epithelium. Am J Surg Pathol 1998;22: 1247-1254.
6. Hoorens A, Prenzel K, Lemoine NR, et al. Undifferentiated carcinoma of the pancreas: analysis of intermediate filament profile and Ki-ras mutations provides evidence of a ductal origin. J Pathol 1998;185: 53-60.
7. Sedivy R, Kalipciyan M, Mazal PR, et al. Osteoclastlike giant cell tumor in mucinous cystadenocarcinoma of the pancreas: an immunohistochemical and molecular analysis. Cancer Detect Prev 2005;29: 8-14.
8. Soh J, Okumura N, Lockwood WW, et al. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One 2009;4:e7464.
9. Aguirre AJ, Bardeesy N, Sinha M, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003;17: 3112-3126.
10. Gandhi J, Zhang J, Xie Y, et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One 2009;4:e4576.
11. Mitsudomi T, Viallet J, Mulshine JL, et al. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 1991;6: 1353-1362.
12. Chiosea SI, Sherer CK, Jelic T, et al. KRAS mutant allele-specific imbalance in lung adenocarcinoma. Mod Pathol 2011;24: 1571-1577.
13. Hartman DJ, Davison JM, Foxwell TJ, et al. Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival. Int J Cancer 2012;131: 1810-1817.
14. Qiu W, Sahin F, Iacobuzio-Donahue CA, et al. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo. Oncotarget 2011;2: 862-873.
15. Sugio K, Molberg K, Albores-Saavedra J, et al. K-ras mutations and allelic loss at 5q and 18q in the development of human pancreatic cancers. Int J Pancreatol 1997;21: 205-217.
16. Heidenblad M, Jonson T, Mahlamaki EH, et al. Detailed genomic mapping and expression analyses of 12p amplifications in pancreatic carcinomas reveal a 3.5-Mb target region for amplification. Genes Chromosomes Cancer 2002;34: 211-223.
17. Aoki Y, Hosaka S, Tachibana N, et al. Reassessment of K-ras mutations at codon 12 by direct PCR and sequencing from tissue microdissection in human pancreatic adenocarcinomas. Pancreas 2000;21: 152-157.
18. Bos JL. The ras gene family and human carcinogenesis. Mutat Res 1988;195: 255-271.
19. Yamada H, Sakamoto H, Taira M, et al. Amplifications of both c-Ki-ras with a point mutation and c-myc in a primary pancreatic cancer and its metastatic tumors in lymph nodes. Jpn J Cancer Res 1986;77: 370-375.
20. Aguirre AJ, Brennan C, Bailey G, et al. High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci USA 2004;101: 9067-9072.
21. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual, 7th edn. Springer-Verlag: New York, 2010.
22. Chiosea S, Shuai Y, Cieply K, et al. EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations. Hum Pathol 2010;41: 1053-1060.
23. Wagner PL, Perner S, Rickman DS, et al. In situ evidence of KRAS amplification and association with increased p21 levels in non-small cell lung carcinoma. Am J Clin Pathol 2009;132: 500-505.
24. Modrek B, Ge L, Pandita A, et al. Oncogenic activating mutations are associated with local copy gain. Mol Cancer Res 2009;7: 1244-1252.
25. Zhang Z, Wang Y, Vikis HG, et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet 2001;29: 25-33.
26. Li J, Zhang Z, Dai Z, et al. LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer. Oncogene 2003;22: 1243-1246.
27. Li H, Cao HF, Wan J, et al. Growth inhibitory effect of wild-type Kras2 gene on a colonic adenocarcinoma cell line. World J Gastroenterol 2007;13: 934-938.
28. Bardeesy N, Aguirre AJ, Chu GC, et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 2006;103: 5947-5952.
29. Oakley GJ 3rd, Chiosea SI. Higher dosage of the epidermal growth factor receptor mutant allele in lung adenocarcinoma correlates with younger age, stage IV at presentation, and poorer survival. J Thorac Oncol 2011;6: 1407-1412.
30. Bachmann J, Michalski CW, Martignoni ME, et al. Pancreatic resection for pancreatic cancer. HPB (Oxford) 2006;8: 346-351.
31. American Cancer SocietyCancer Facts & Figures (accessed 5 January 2013). Available from http://www. cancer.org/Research/CancerFactsFigures/index.
32. Feldser DM, Kostova KK, Winslow MM, et al. Stagespecific sensitivity to p53 restoration during lung cancer progression. Nature 2011;468: 572-575.
33. Junttila MR, Karnezis AN, Garcia D, et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 2011;468: 567-571.